Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents

Karin Helwig, Colin Hunter, John MacLachlan, Moyra McNaughtan, Joanne Roberts, Alex Cornelissen, Christophe Dagot, Herman Evenblij, Kai Klepiszewski, Lyko Sven, Issa Nafo, Christa McArdell, Ole Pahl

Research output: Contribution to journalArticle

15 Downloads (Pure)

Abstract

A method is described for the identification of priority micropollutants (pharmaceuticals) in the aquatic environment originating from hospitals. The lack of data on the range and volume of prescribed pharmaceuticals, and on their behaviour in the environment, presented a considerable challenge to the initial selection process. The final selection of pharmaceutical substances to be included in the monitoring campaigns was based on literature data, existing priority lists, national consumption patterns and expert input from within the regions (Northwest Europe). Fifteen micropollutant compounds were identified from the diverse range of reported and prescribed pharmaceuticals in the healthcare sector:atenolol, carbamazepine, diclofenac, naproxen, lidocaine, ifosphamide, cyclophosphamide, ciprofloxacin, erythromycin, clarithromycin, sulfamethoxazole, iopromide, iopamidol, diatrizoate, and bezafibrate. Eight hospital locations in six countries were monitored for periods ranging from several weeks to one year.
Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalJournal of Environmental & Analytical Toxicology
Volume3
Issue number4
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Drug products
point source
Effluents
drug
effluent
iopromide
Monitoring
monitoring
Pharmaceutical Preparations
Iopamidol
Bezafibrate
Diatrizoate
Sulfamethoxazole
Naproxen
Health Care Sector
Atenolol
Clarithromycin
Diclofenac
Carbamazepine
Erythromycin

Keywords

  • pharmaceuticals
  • micropollutants
  • point sources
  • hospitals
  • prioritisation
  • environmental monitoring

Cite this

Helwig, Karin ; Hunter, Colin ; MacLachlan, John ; McNaughtan, Moyra ; Roberts, Joanne ; Cornelissen, Alex ; Dagot, Christophe ; Evenblij, Herman ; Klepiszewski, Kai ; Sven, Lyko ; Nafo, Issa ; McArdell, Christa ; Pahl, Ole. / Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents. In: Journal of Environmental & Analytical Toxicology. 2013 ; Vol. 3, No. 4. pp. 1-10.
@article{67ec0e28d435403e9b6052f508f2d97b,
title = "Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents",
abstract = "A method is described for the identification of priority micropollutants (pharmaceuticals) in the aquatic environment originating from hospitals. The lack of data on the range and volume of prescribed pharmaceuticals, and on their behaviour in the environment, presented a considerable challenge to the initial selection process. The final selection of pharmaceutical substances to be included in the monitoring campaigns was based on literature data, existing priority lists, national consumption patterns and expert input from within the regions (Northwest Europe). Fifteen micropollutant compounds were identified from the diverse range of reported and prescribed pharmaceuticals in the healthcare sector:atenolol, carbamazepine, diclofenac, naproxen, lidocaine, ifosphamide, cyclophosphamide, ciprofloxacin, erythromycin, clarithromycin, sulfamethoxazole, iopromide, iopamidol, diatrizoate, and bezafibrate. Eight hospital locations in six countries were monitored for periods ranging from several weeks to one year.",
keywords = "pharmaceuticals, micropollutants, point sources, hospitals, prioritisation, environmental monitoring",
author = "Karin Helwig and Colin Hunter and John MacLachlan and Moyra McNaughtan and Joanne Roberts and Alex Cornelissen and Christophe Dagot and Herman Evenblij and Kai Klepiszewski and Lyko Sven and Issa Nafo and Christa McArdell and Ole Pahl",
note = "Duplicate entry deleted 25-4-18 (created by KHE)",
year = "2013",
month = "7",
doi = "10.4172/2161-0525.1000177",
language = "English",
volume = "3",
pages = "1--10",
journal = "Journal of Environmental & Analytical Toxicology",
issn = "2161-0525",
publisher = "OMICS International",
number = "4",

}

Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents. / Helwig, Karin; Hunter, Colin; MacLachlan, John; McNaughtan, Moyra; Roberts, Joanne; Cornelissen, Alex; Dagot, Christophe ; Evenblij, Herman; Klepiszewski, Kai; Sven, Lyko; Nafo, Issa; McArdell, Christa; Pahl, Ole.

In: Journal of Environmental & Analytical Toxicology, Vol. 3, No. 4, 07.2013, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Micropollutant point sources in the built environment: identification and monitoring of priority pharmaceutical substances in hospital effluents

AU - Helwig, Karin

AU - Hunter, Colin

AU - MacLachlan, John

AU - McNaughtan, Moyra

AU - Roberts, Joanne

AU - Cornelissen, Alex

AU - Dagot, Christophe

AU - Evenblij, Herman

AU - Klepiszewski, Kai

AU - Sven, Lyko

AU - Nafo, Issa

AU - McArdell, Christa

AU - Pahl, Ole

N1 - Duplicate entry deleted 25-4-18 (created by KHE)

PY - 2013/7

Y1 - 2013/7

N2 - A method is described for the identification of priority micropollutants (pharmaceuticals) in the aquatic environment originating from hospitals. The lack of data on the range and volume of prescribed pharmaceuticals, and on their behaviour in the environment, presented a considerable challenge to the initial selection process. The final selection of pharmaceutical substances to be included in the monitoring campaigns was based on literature data, existing priority lists, national consumption patterns and expert input from within the regions (Northwest Europe). Fifteen micropollutant compounds were identified from the diverse range of reported and prescribed pharmaceuticals in the healthcare sector:atenolol, carbamazepine, diclofenac, naproxen, lidocaine, ifosphamide, cyclophosphamide, ciprofloxacin, erythromycin, clarithromycin, sulfamethoxazole, iopromide, iopamidol, diatrizoate, and bezafibrate. Eight hospital locations in six countries were monitored for periods ranging from several weeks to one year.

AB - A method is described for the identification of priority micropollutants (pharmaceuticals) in the aquatic environment originating from hospitals. The lack of data on the range and volume of prescribed pharmaceuticals, and on their behaviour in the environment, presented a considerable challenge to the initial selection process. The final selection of pharmaceutical substances to be included in the monitoring campaigns was based on literature data, existing priority lists, national consumption patterns and expert input from within the regions (Northwest Europe). Fifteen micropollutant compounds were identified from the diverse range of reported and prescribed pharmaceuticals in the healthcare sector:atenolol, carbamazepine, diclofenac, naproxen, lidocaine, ifosphamide, cyclophosphamide, ciprofloxacin, erythromycin, clarithromycin, sulfamethoxazole, iopromide, iopamidol, diatrizoate, and bezafibrate. Eight hospital locations in six countries were monitored for periods ranging from several weeks to one year.

KW - pharmaceuticals

KW - micropollutants

KW - point sources

KW - hospitals

KW - prioritisation

KW - environmental monitoring

U2 - 10.4172/2161-0525.1000177

DO - 10.4172/2161-0525.1000177

M3 - Article

VL - 3

SP - 1

EP - 10

JO - Journal of Environmental & Analytical Toxicology

JF - Journal of Environmental & Analytical Toxicology

SN - 2161-0525

IS - 4

ER -